6
INAF0306.TXT

INAF
Indofarma Tbk
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 30-Jun-2003
Fiscal Year Ends            : Dec
Months Covered in Income St : 6

Summary of Balance Sheet
  Receivables               :      97,676,393.15
  Inventories               :     296,394,902.42
  Current Assets            :     540,012,069.42
  Fixed Assets              :     120,463,702.74
  Other Asstes              :      19,037,861.77
  Total Assets              :     711,131,081.97
  Current Liabilities       :     308,385,708.25
  Longterm Liabiities       :      39,615,203.86
  Total Liabilities         :     348,000,912.11
  Authorized                :      10,000,000.00
  Paid-up Capital           :     309,926,750.00
  Par Value                 :                100
  Paid-up Capital Shares    :       3,099,267.50
  Retained Earnings         :     -28,620,208.56
  Total Equity              :     356,406,897.62
  Minority Interest         :       6,723,272.23

Summary of Income Statement
  Total Sales               :     166,944,773.80
  Cost of Good Sold         :     113,685,974.85
  Gross Profit              :      53,258,798.95
  Operating Profit          :     -25,197,017.62
  Other Income              :     -16,814,213.88
  Eearning Before Tax       :     -42,011,231.50
  Tax                       :      -7,152,591.63
  Net Income                :     -34,028,602.88
  Closing Price             :             180.00

Per Share Data (Rp)
  Eps                       :             -21.96
  Book Value                :             115.00

Financial Ratios
  Debt Equity Ratio (X)     :                .98
  Roa (%)                   :              -9.57
  Roe (%)                   :             -19.10
  Npm (%)                   :             -40.77
  Opm (%)                   :             -30.19

Cash Flow
  CF from Operating Activities                        :     -69,615,180.74
  CF from Investing Activities                        :      -4,187,375.93
  CF from Financing Activities                        :      42,948,690.56
  Net Increase in Cash & Cash Equivalent              :     -30,853,866.11
  Cash & Cash Equivalent at The Beginning of The Year :      48,171,949.67
  Cash & Cash Equivalent at The End of The Year       :      16,879,753.43

 
 
 
